In the last decade, it has been increasingly recognized that antidepressant drugs may exert a range of effects, in addition to their well-documented ability to modulate neurotransmission. Although as a group they act on monoaminergic systems and receptors in different ways, a number of studies have demonstrated that at least some antidepressants might have other properties in common, including immunomodulatory, cyto/neuroprotective, analgesic and anti-inflammatory activities. These properties are partly related to the influence of antidepressants on glial cell function.
Recently, emerging information about the possible anticancer properties of antidepressants has sparked increased interest within scientific community, and there is now evidence that these drugs affect the key cellular mechanisms of carcinogenesis. This review examines the putative cellular targets for the anticancer action of antidepressant drugs, and presents examples of the interaction between antidepressants and anticancer drugs. By reviewing the current state of research in this area, we hope to focus the attention of oncologists and researchers engaged in the study of cancer on the role that antidepressant drugs could play in the complementary therapy of cancer.
EckertA. Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch2009, pp. 485–92.
2.
SternbachH. Are antidepressants carcinogenic? A review of preclinical and clinical studies. J Clin Psychiatry2003, pp. 1153–62.
3.
ShusterJLSternTA. Pros and cons of fluoxetine for the depressed cancer patient. Oncology1992, pp. 45–56.
4.
SteingartABCotterchioM. Do antidepressants cause, promote, or inhibit cancers?J Clin Epidemiol1995, pp. 1407–12.
5.
AshkenaziAHerbstRS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest2008; 118: 1979–90.
6.
RikiishiH. Apoptotic cellular events for selenium compounds involved in cancer prevention. J Bioenerg Biomembr2007; 39: 91–8.
7.
CreeIA. Cancer biology. Methods Mol Biol2011; 731: 1–11.
8.
ValeroJGSanceyLKucharczakJGuilleminYGimenezDPrudentJGilletGSalgadoJCollJLAouacheriaA. Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells. J Cell Sci2011; 15: 556–64.
9.
CichorekMKozłowskaKWachulskaMZielińskaK. Spontaneous apoptosis of melanotic and amelanotic melanoma cells in different phases of cell cycle: relation to tumor growth. Folia Histochem Cytobiol2006; 44: 31–6.
10.
MaJQiuYYangLPengLXiaZHouLNFangCQiHChenHZ. Desipramine induces apoptosis in rat glioma cells via endoplasmic reticulum stress-dependent CHOP pathway. J Neurooncol2011; 101: 41–8.
11.
OrdysBBLaunaySDeightonRFMcCullochJWhittleIR. The role of mitochondria in glioma pathophysiology. Mol Neurobiol2010; 1: 64–75.
12.
RakeshKJ. Normalization of the tumor vasculature: an emerging concept in antangiogenic therapy. Science2005; 1: 58–62.
13.
ArimochiHMoritaK. Desipramine induces apoptotic cell death through nonmitochondrial and mitochondrial pathways in different types of human colon carcinoma cell. Pharmacology2008; 2: 164–72.
14.
PiccottiJRLaGattulataMSKnightSAGonzalesAJBlevinisMR. Induction of apoptosis by cationic amphiphilic drugs amiodarone and imipramine. Drug Chem Toxicol2005; 28: 117–33.
15.
SerafeimAGraftonGChambaAGregoryCDBlakelyRDBoweryNGBarnesNMGordonJ. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood2002; 1: 2545–53.
16.
LevkovitzYGil-AdIZeldichEDayagMWeizmanA. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci2005; 27: 29–42.
17.
ReddyKKLefkoveBChenLBGovindarajanBCarracedoAVelascoGCarrilloCOBhandarkarSSOwensMJMechta-GrigoriouFArbiserJL. The antidepressant sertraline downregulates Akt and has activity against melanoma cells. Melanoma Res2008; 21: 451–6.
18.
GalluziiLMorselliEVicencioJMKeppNOJozaNTajjeddineNKroemerG. Life, death and burial: multifaceted impact of autophagy. Biochem Soc Trans2008; 36: 786–90.
19.
KunduMThompsonCB. Basic principles and relevance to diseases. Annu Rev Pathol2008; 3: 427–55.
20.
TorricelliCSalvadoriSValacchiGSoučekKSlabákováEMuscettolaMVolpiNMaioliE. Alternative pathways of cancer cell death by Rottlerin: apoptosis versus autophagy. Evid Based Complement Alternat Med2012; 2012: 980658–980658.
21.
CloonamSMWilliamsDC. The antidepressants maprotiline and fluoxetine induce type II autophagic cell death in drug-resistant Burkitt's lymphoma. Int J Cancer2011; 7: 1712–23.
22.
BrechAAhlquistTLotheRAStenmarkH. Autophagy in tumour suppression and promotion. Mol Oncol2009; 3: 366–75.
Abdel RazaqWKendallDABatesTE. The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem Res2011; 36: 327–8.
25.
BulteauALBayotA. Mitochondrial proteases and cancer. Biochem Biophys Acta2010, pp. 1–7.
26.
ColquhounA. Lipids, mitochondria and cell death: implications in neuro-oncology. Mol Neurobiol2010; 42: 76–88.
27.
HroudovaJFisarZ. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinol Lett2010; 31: 336–42.
28.
PilkingtonGJParkerKMurraySA. Approaches to mitochondrially mediated cancer therapy. Semin Cancer Biol2008; 18: 226–35.
29.
RalphSJRodriguez-EnriguezSNeuzilJSaavedraEMoreno-SanchezR. The causes of cancer revisited: “Mitochondrial malignancy” and ROS induced oncogenic transformation – why mitochondria are targets for cancer therapy. Mol Aspects Med2010; 31: 145–170.
30.
RamsayEEHoggPJDildaPJ. Mitochondrial metabolism inhibitors for cancer therapy. Pharm Res2011; 28: 2731–44.
31.
WolfAAgnihotriSGuhaA. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget2010; 1: 552–62.
HigginsSCPilkingtonGJ. The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res2010; 30: 391–7.
34.
DiwuZ. Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Photochem Photobiol1995; 61: 529–39.
35.
DaleyEWilkieDLoeschAHargreavesIPKendallDAPilkingtonGJBatesTE. Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun2005; 11: 623–32.
36.
PyrzynskaBSerranoMMartínezACKaminskaB. Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin A. J Biol Chem2002; 19: 14102–8.
37.
SrebroZ. [Immunological phenomena and carcinogenesis]. Postepy Hig Med Dosw1971; 25: 391–414.
38.
BellamyCO. P53 and apoptosis. Br Med Bull1997; 53: 522–38.
39.
KrishnanAHariharanRNairSAPillaiMR. Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol2008; 15: 1924–34.
40.
StepulakARzeskiWSifringerMBrockeKGratoppSKupiszKTurskiLIkonomidouC. Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther2008; 7: 1685–93.
41.
GrekCLTewKD. Redox metabolism and malignancy. Curr Opin Pharmacol2010; 10: 362–8.
42.
KrystonTBGeorgievABPissisPGeorgakilasAG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res2011; 3: 193–201.
43.
Di Domenico F, Foppoli C, Coccia R, Perluigi M. Antioxidants in cervical cancer: chemopreventive and chemotherapeutic effects of polyphenols. Biochim Biophys Acta. Epub ahead of print 12 October 2011. DOI: 10.1016/j.bbadis.2011.10.005.
44.
ReuterVE. Origins and molecular biology of testicular germ cell tumors. Mol Pathol2005; 2: 51–60.
45.
KirkovaMTzvetanovaEVirchevaSZamfirovaRGrygierBKuberaM. Antioxidant activity of fluoxetine: studies in mice melanoma model. Cell Biochem Func2010; 6: 497–502.
46.
FerraraN. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw2009; 20: 158–63.
BhuvaneswariRGanYYLuckySSChinWWAliSMSooKCOlivoM. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol Cancer2008; 13: 7–56.
49.
LorussoGVanniniNSognoIGenerosoLGarbisaSNoonanDMAlbiniA. Mechanisms of hyperforin as an anti-angiogenic angioprevention agent. Eur J Cancer2009; 8: 1474–84.
50.
SchmidtHDDumanRS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol2007; 18: 391–418.
51.
KuberaMGrygierBArtetaBUrbańskaKBasta-KaimABudziszewskaBLeśkiewiczMKołaczkowskaEMaesMSzczepanikMMajewskaMLasońW. Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacol Rep2009; 6: 1113–26.
52.
FrancoRSchoneveldOGeorgakilasAGPanayiotidisMI. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett2008; 1: 6–11.
53.
EkbomABrandtLGranathFLöfdahlCGEgestenA. Increased risk of both ulcerative colitis and Crohn's disease in a population suffering from COPD. Lung2008; 3: 167–72.
54.
DeNardoDGCoussensLM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res2007; 4: 204–12.
55.
HarendeemJMLindleyC. Use of NSAIDs for the chemoprevention of colorectal cancer. Ann Pharmacother2003; 11: 1664–74.
56.
AsciertoMLDe GiorgiVLiuQBedognettiDSpiveyTLMurtasDUccelliniLAyotteBDStroncekDFChouchaneLManjiliMHWangEMarincolaFMJ. An immunologic portrait of cancer. Transl Med2011; 9: 119–46.
57.
KuberaMLinAHKenisGBosmansEvan BockstaeleDMaesM. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol2001; 2: 199–206.
Ben-NeriahYKarinM. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol2011; 19: 715–23.
60.
KohSJKimJMKimIKKimNJungHCSongISKimJS. Fluoxetine inhibits NF-κB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am J Physiol Gastrointest Liver Physiol2011; 30: 9–19.
61.
GordonJBarnesNM. Lymphocytes transport serotonin and dopamine: agony or ecstasy?Trends Immunol2003; 24: 438–43.
62.
SchiepersOJWichersMCMaesM. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry2005; 29: 201–11.
63.
ParianteCMThomasSALovestoneSMakoffAKerwinRW. Do antidepressants regulate how cortisol affects the brain?Psychoneuroendocrinology2004; 29: 423–47.
64.
Volden PA, Conzen SD. The influence of glucocorticoid signaling on tumor progression. Brain Behav Immun. Epub ahead of print 16 November 2012. DOI: 10.1016/j.bbi.2012.10.022.
65.
CotterchioMKreigerNDarlingtonGSteingartA. Antidepressant medication use and breast cancer risk. Am J Epidemiol2000; 15: 951–7.
66.
CosgroveLShiLCreaseyDEAnaya-McKiverganMMyersJAHuybrechtsKF. Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry. PLoS One2011; 6: 18210–18210.
67.
MaoXHouTCaoBWangWLiZChenSFeiMHurrenRWuDTrudelSAchimmerAD. The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. Mol Pharmacol2011; 4: 672–80.
68.
ReuterSGuptaSCChaturvediMMAggarwalBB. Oxidative stress, inflammation, and cancer: how are they linked?Free Radic Biol Med2010, pp. 1603–16.
69.
HideshimaTBergsagelPLKuehlWMAndersonKC. Advances in biology of multiple myeloma: clinical applications. Blood2004; 3: 607–18.
70.
Barillé-NionSBarlogieBBatailleRBergsagelPLEpsteinJFentonRGJacobsonJKuehlWMShaughnessyJTricotG. Advances in biology and therapy of multiple myeloma. Hematol Am Soc Hematol Educ Program2003, pp. 248–78..
71.
BrandesLJArronRJBogdanovicRPTongJZaborniakCLHoggGRWarringtonRCFangWLaBellaFS. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res1992; 13: 3796–800.
72.
TamimHMMahmudSHanleyJABoivinJFStangMRColletJP. Antidepressants and risk of prostate cancer: a nested case-control study. Prostate Cancer Prostatic Dis2008; 11: 53–60.
73.
DaltonSOPoulsenAHNørgaardMMcLaughlinJKJohansenCFriisS. Tricyclic antidepressants and non-Hodgkin lymphoma. Epidemiology2008; 4: 546–9.
74.
IngramDMNottageEMRobertsAN. Prolactin and breast cancer risk. Med J Aust1990; 8: 469–73.
75.
BreitbartW. Do antidepressants reduce the effectiveness of tamoxifen?Psychooncology2011; 1: 1–4.
76.
PritchardKI. Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?Breast Cancer2010; 4: 12–20.
77.
KellyCMJurlinkDNGomesTDuong-HuaMPritchardKIAustinPCPaszatLF. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ2010; 340: c693–c693.
78.
PeerDMargalitR. Fluoxetine and reversal of multidrug resistance. Cancer Lett2006; 2: 180–7.
79.
WernliKJHamptonJMTrentham-DietzANewcombPA. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivor. Pharmacoepidemiol Drug Saf2011; 2: 131–7.
80.
AshburyJELévesqueLEBeckPAAronsonKJ. A population-based case-control study of selective serotonin reuptake inhibitors (SSRIs) and breast cancer: the impact of duration of use, cumulative dose and latency. BMC Med2010; 22: 80–90.
81.
PommerenkeEMatternJVolmM. Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo. J Cancer Res Clin Oncol1994; 120: 422–6.
82.
TsuruoTLidaHNojiriMTsukagoshiSSakuariY. Potentiation of chemotherapeutic effect of vincristine in vincristine resistant tumor bearing mice by calmodulin inhibitor clomipramine. J Pharmacobiodyn1983; 6: 145–7.
83.
MerrySHamiltonTGFlaniganPFreshneyRIKayeSB. Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur J Cancer1991; 27: 31–4.
84.
FlamandVZhaoHPeehlDM. Targeting monoamine oxidase A in advanced prostate cancer. J Cancer Res Clin Oncol2010; 11: 1761–71.
85.
TuttonPJBarklaDH. Cell proliferation in the descending colon of dimethylhydrazine treated rats and in dimethylhydrazine induced adenocarcinomata. Virchows Arch B Cell Pathol1976; 2: 147–60.
86.
XiaZLundgrenBBergstrandADePierreJWNässbergerL. Changes in the generation of reactive oxygen species and mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and citalopram and the effects on these changes by Bcl-2 and Bcl-X. Biochem Pharmacol1999, pp. 1199–208.
87.
BilirAErguvenMOktemGOzdemirAAktasEBonavidaB. Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. Int J Oncol2008, pp. 829–39.
88.
LeeCSKimYJJangERKimWMyungSC. Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin Pharmacol Toxicol2010; 6: 446–53.
89.
ParkerKAGlaysherSHurrenJKnightLAMcCormickDSuovouriAAmberger-MurphyVPilkingtonGJCreeIA. The effect of tricyclic antidepressants on cutaneous melanoma cell lines and primary cell cultures. Anticancer Drugs2012; 23: 65–9.
90.
HisaokaKTakebayashiMTsuchiokaMMaedaNNakataYYamawakiS. Glia as targets for antidepressants: an involvement in glial cell line-derived neurotrophic factor. J Pharmacol Exp Ther2007, pp. 148–57.
91.
PollakYYirmiyaR. Cytokine-induced changes in mood and behaviour: implications for ‘depression due to a general medical condition, immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol2002, pp. 389–99.
92.
WuSTSunGHHsuCYHuangCSWuYHWangHHSunKH. Tumor necrosis factor-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a nuclear factor kappa B-independent mechanism. Exp Biol Med (Maywood)2011; 9: 1022–9.
WeichertW. HDAC expression and clinical prognosis in human malignancies. Cancer Lett2009; 8: 168–76.
95.
MunshiAKurlandJFNishikawaTTanakaTHobbsMLTuckerSLIsmailSStevensCMeynRE. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res2005; 11: 4912–22.
96.
HuJColburnNH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res2005; 3: 100–9.
97.
TuttonPJBarklaDH. Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinoma. Br J Cancer1982, pp. 260–5.
98.
SauterC. Cytostatic activity of commonly used tricyclic antidepressants. Oncology1989; 46: 155–7.
